Revolution Medicines
$RVMD · NASDAQ · 2 stories in 30 daysThe wire on $RVMD
newest first · duplicate source posts collapse into one event · direct subject stories onlyRubrik Q2 revenue and EPS beat estimates; lifts FY27 guidance
Rubrik Q2 revenue $427.3M vs est. $396M, adj EPS $0.20 vs est. $0.04, FCF $65.7M vs est. $39.7M. Subscription ARR +33% YoY to $1.66B. FY27 revenue guide raised to $1.685B-$1.693B (est. $1.64B), EPS to $0.47-$0.53 (est. $0.31). Q3 revenue guide $429M-$431M above $418M est.
bullish 80 · impact 60Revolution Medicines price target raised to $270 at Jefferies
Jefferies raised its price target on Revolution Medicines to $270 from $242.
bullish 65 · impact 30The wire on this name is open. What the tape did about it is one free account away.
One free account opens 3 complete views a day on any story, ticker or report. No card. The wire stays free to read.
- News on Price
- Earnings read
- Flow and ownership
- Options context
the wire stays free to read · BORSA Plus: start 3 days free, then $49.99 a year or $9.99 a month